A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo [0.03%]
芬戈莫德与安慰剂中断治疗后多发性硬化疾病活动的比较研究
Patrick Vermersch,Ernst-Wilhelm Radue,Norman Putzki et al.
Patrick Vermersch et al.
Background: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. Objective: The obje...
M P Alvarenga,Sergio Schimidt,Rm Papais Alvarenga
M P Alvarenga
A major development over the past two decades was the recognition of recurrent neuromyelitis optica (NMO) as a particular central nervous system disorder different from multiple sclerosis (MS). Here we reviewed the epidemiology of NMO in La...
Verónica Rivas Alonso,José de Jesús Flores Rivera,Yamel Rito García et al.
Verónica Rivas Alonso et al.
Background: In today's globalised world, the heterogeneity of diseases such as multiple sclerosis has been studied since it has been suggested that ethnic differences, in conjunction with geographical and environmental fa...
Lilyana Amezcua,Jorge R Oksenberg,Jacob L McCauley
Lilyana Amezcua
Self-identified Hispanic/Latino individuals living with multiple sclerosis (MS) in the continental United States (US) are a diverse group that represents different cultural and ancestral backgrounds. A marked variability in the way MS affec...
Eli Skromne-Eisenberg,Laura Ordoñez-Boschetti,Irene Treviño-Frenk
Eli Skromne-Eisenberg
The treatment of multiple sclerosis (MS) has become increasingly complex during the last 10 years, mainly because of the advent of new and more potent disease-modifying therapies (DMTs). In Latin America, the therapeutic repertoire availabl...
Liliana Patrucco
Liliana Patrucco
The diagnosis of multiple sclerosis (MS) is based on neurological symptoms and signs, alongside evidence of dissemination of central nervous system (CNS) lesions in space and time. In the absence of a sensitive and specific diagnostic test,...
The challenges and opportunities of multiple sclerosis care in Latin America [0.03%]
拉美地区多发性硬化症治疗的挑战与机遇
Daniel Ontaneda,Jorge Correale
Daniel Ontaneda
Cognitive and neuropsychiatric disorders among MS patients from Latin America [0.03%]
拉丁美洲多发性硬化患者的认知和神经精神障碍
Sandra Vanotti,Fernando J Caceres
Sandra Vanotti
Cognitive and neuropsychiatric disorders in patients with multiple sclerosis have been extensively documented. The focus of this review will be on cognitive and neuropsychiatric disorders in multiple sclerosis patients from Latin America, i...
Y D Fragoso,F G Elso,A Carrá
Y D Fragoso
Improvement of multiple sclerosis (MS) diagnoses leads to earlier and correct disease management. The differential diagnostic workup for MS comprises a large variety of medical conditions. There are general guidelines and criteria for diagn...
Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale [0.03%]
多国临床试验中患者报告结果测量等价性检验：利用12项多发性硬化行走量表进行演示
Hussein Dib,Yusuf Tamam,Murat Terzi et al.
Hussein Dib et al.
Background: Although multinational clinical trials frequently use patient-reported outcomes to measure efficacy, measurement equivalence across cultures and languages, a scientific requirement, is rarely tested. Clinicall...